← Leaderboards
Gretchen L Snyder
Rockefeller University
$2,753,105
Attributed
$6,863,908
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2014–21$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$6,863,908 · 5
By mechanism
UG3$6,166,204 · 1
R43$697,704 · 2
P01$0 · 2
Top collaborators
- Sandra D. Comer2 shared
- Dean Foster Wong2 shared
Most similar at Rockefeller University
Same institution · by research overlap
- Paul Greengard$29,785,859
- Michael W Young$19,457,879
- Angus C. Nairn$15,314,298
- Andrew J Czernik$2,053,316
- Per Svenningsson$1,396,030
Others in their field
Top investigators on “Dopamine”
- Pedro A. Jose · George Washington University$34,248,029
- Jonathan A Javitch · Columbia University Health Sciences$28,566,988
- Michael A Nader · Emory University$26,344,520
- Dalton James Surmeier · University Of Tennessee Health Sci Ctr$23,527,588
- Michael A Schwarzschild · Massachusetts General Hospital$22,973,787
- David Sulzer · Columbia University Health Sciences$22,837,505
Research focus
DopamineLaboratory MouseLaboratory RatDarppPhosphorylationGlutamate ReceptorBiological Signal TransductionPhosphatase InhibitorEnzyme ActivityCyclin Dependent KinaseSignal TransductionPlasmaProtein KinaseBrainCentral Nervous System DiseasesProgramsSmall MoleculePharmaceutical PreparationsPharmacologic SubstanceInnovationAnxietyBaseBiotechnologyGaba Receptor
Grant awards (9)
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders$2,917,074
UG3 · FY2021 · DA · contact PI
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders$3,249,130
UG3 · FY2019 · DA · contact PI
Development of PDE2 Inhibitors for Treatment of Anxiety/Depression in Autism/Schizophrenia$348,094
R43 · FY2016 · MH · contact PI
Casein Kinase 1 Inhibitors for Treatment of Autism$349,610
R43 · FY2014 · MH · contact PI
PHARMACOLOGICAL REGULATION OF BASAL GANGLIA ENRICHED PHOSPHOPROTEIN$0
P01 · FY2002 · MH
DRUGS OF ABUSE: ROLE OF Cdk5 IN THE ACTIONS OF PSYCHOSTIMULANTS$0
P01 · FY2002 · DA
PHARMACOLOGICAL REGULATION OF BASAL GANGLIA ENRICHED PHOSPHOPROTEIN$0
P01 · FY2001 · MH
DRUGS OF ABUSE: ROLE OF Cdk5 IN THE ACTIONS OF PSYCHOSTIMULANTS$0
P01 · FY2001 · DA
PHARMACOLOGICAL REGULATION OF BASAL GANGLIA ENRICHED PHOSPHOPROTEIN$0
P01 · FY2000 · MH